Prescribing information



Welcome to the TAFINLAR® + MEKINIST® on-demand webinars page.

Below you can access recordings of the latest educational webinars organised by Novartis and hosted by experts in the field of lung cancer. We’ll continue to add to the collection, so keep checking back!


Targeted therapy for BRAF+ NSCLC patients

Dr Tom Newsom-Davis, Dr Alastair Greystoke, Dr Riyaz Shah and Dr Toby Talbot come together to discuss the current testing landscape, the clinical data for Dabfrafenib+Trametinib in NSCLC and what can be learnt from the clinical experience in the melanoma setting.

Register to watch the full video
or specific topic highlights


Indication: Tafinlar in combination with Mekinist is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.


  1. Tafinlar (dabrafenib) Summary of Product Characteristics.
  2. Mekinist (trametinib) Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | April 2021 | 118583

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]